Fulton Bank N.A. Acquires 211 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Fulton Bank N.A. boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 7.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,070 shares of the medical equipment provider’s stock after buying an additional 211 shares during the period. Fulton Bank N.A.’s holdings in Intuitive Surgical were worth $1,508,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. Miracle Mile Advisors LLC increased its position in Intuitive Surgical by 7.7% in the 3rd quarter. Miracle Mile Advisors LLC now owns 1,805 shares of the medical equipment provider’s stock worth $887,000 after buying an additional 129 shares during the period. Consilio Wealth Advisors LLC acquired a new stake in shares of Intuitive Surgical during the 3rd quarter worth approximately $218,000. GAMMA Investing LLC grew its holdings in shares of Intuitive Surgical by 31.2% during the 3rd quarter. GAMMA Investing LLC now owns 5,090 shares of the medical equipment provider’s stock worth $2,501,000 after purchasing an additional 1,211 shares in the last quarter. Handelsbanken Fonder AB grew its holdings in shares of Intuitive Surgical by 42.2% during the 3rd quarter. Handelsbanken Fonder AB now owns 192,542 shares of the medical equipment provider’s stock worth $94,590,000 after purchasing an additional 57,124 shares in the last quarter. Finally, Burns J W & Co. Inc. NY grew its holdings in shares of Intuitive Surgical by 8.7% during the 3rd quarter. Burns J W & Co. Inc. NY now owns 9,827 shares of the medical equipment provider’s stock worth $4,828,000 after purchasing an additional 790 shares in the last quarter. 83.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several recent research reports. JPMorgan Chase & Co. lifted their price objective on Intuitive Surgical from $475.00 to $495.00 and gave the stock an “overweight” rating in a report on Friday, July 19th. Evercore ISI lifted their price objective on Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. BTIG Research lifted their price objective on Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Finally, Piper Sandler boosted their price target on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $449.70.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $471.23 on Tuesday. The firm has a market cap of $167.15 billion, a P/E ratio of 85.06, a P/E/G ratio of 5.39 and a beta of 1.39. The business’s fifty day moving average is $476.55 and its two-hundred day moving average is $432.12. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.18 earnings per share. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other news, insider Mark Brosius sold 2,115 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $491.91, for a total transaction of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares in the company, valued at $145,113.45. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total value of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares in the company, valued at approximately $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Mark Brosius sold 2,115 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now owns 295 shares of the company’s stock, valued at $145,113.45. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,120 shares of company stock worth $25,528,753 over the last 90 days. 0.90% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.